The Oncology Institute, Inc. (TOI) Misses Q3 EPS by 1c; Offers FY22 Revenue Guidance

The Oncology Institute, Inc. (NASDAQ: TOI) reported Q3 EPS of ($0.17), $0.01 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $65 million versus the consensus estimate of $68.91 million.

GUIDANCE:

The Oncology Institute, Inc. sees FY2022 revenue of $245-250 million, versus the consensus of $270.3 million.

For earnings history and earnings-related data on The Oncology Institute, Inc. (TOI) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Arrive AI and DXC Technology partner to bring delivery tech to factories
• Is the S&P 500 in an "earnings bubble"? Goldman weighs in